Goodwill and Intangible Assets, Net (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments

The carrying values of goodwill assigned to the Company’s reporting units are as follows:

	Cell Therapy			Degenerative Disease			Biobanking		Total
Balance at December 31, 2021	$	112,347		$	3,610		$	7,347	$	123,304
Impairment		—			(3,610	)		—		(3,610	)
Balance at December 31, 2022	$	112,347		$	—		$	7,347	$	119,694
Impairment		(112,347	)		—			—		(112,347	)
Balance at December 31, 2023	$	—		$	—		$	7,347	$	7,347

Schedule of Intangible Assets, Net

Intangible assets, net consisted of the following:

	September 30, 2024			December 31, 2023			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810		11 – 16 years
Customer relationships		2,413			2,413		10 years
Trade names & trademarks		570			570		10 – 13 years
Reacquired rights		4,200			4,200		6 years
		23,993			23,993
Less accumulated amortization:
Developed technology		(8,600	)		(7,722	)
Customer relationships		(1,898	)		(1,700	)
Trade names & trademarks		(371	)		(330	)
Reacquired rights		(4,200	)		(3,940	)
		(15,069	)		(13,692	)
Amortizable intangible assets, net		8,924			10,301
Non-amortized intangible assets
Acquired IPR&D product rights		700			700		indefinite
	$	9,624		$	11,001

Intangible assets, net consisted of the following:

	December 31, 2023			December 31, 2022			Estimated Useful Lives
Amortizable intangible assets:
Developed technology	$	16,810		$	16,810		11 – 16 years
Customer relationships		2,413			2,413		10 years
Trade names & trademarks		570			570		10 – 13 years
Reacquired rights		4,200			4,200		6 years
		23,993			23,993
Less: accumulated amortization
Developed technology		(7,722	)		(6,549	)
Customer relationships		(1,700	)		(1,435	)
Trade names & trademarks		(330	)		(275	)
Reacquired rights		(3,940	)		(3,240	)
		(13,692	)		(11,499	)
Amortizable intangible assets, net		10,301			12,494
Non-amortized intangible assets
Acquired IPR&D product rights		700			108,500		indefinite
	$	11,001		$	120,994

Schedule of Aggregate Amortization Expense Related to Intangible Assets

Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December 31, 2023 is estimated as follows:

2024	$	1,753
2025	$	1,493
2026	$	1,356
2027	$	1,258
2028	$	1,208